Aptevo Therapeutics Inc.

0.1994+0.0204+11.40%Vol 501.01K1Y Perf -94.19%
Nov 29th, 2023 16:00 DELAYED
BID0.1952 ASK0.2035
Open0.1790 Previous Close0.1790
Pre-Market- After-Market0.20
 - -  0.01 2.71%
Target Price
18.00 
Analyst Rating
Strong Buy 1.00
Potential %
8.93K 
Finscreener Ranking
★★★★★     68.22
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     68.59
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★★     72.34
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
0.68 
Earnings Rating
Strong Buy
Market Cap3.51M 
Earnings Date
9th Nov 2023
Alpha-0.04 Standard Deviation0.78
Beta5.24 

Today's Price Range

0.17900.2089

52W Range

0.15177.20

5 Year PE Ratio Range

-1.2022.70

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
4.95%
1 Month
-33.53%
3 Months
-52.18%
6 Months
-87.77%
1 Year
-94.19%
3 Years
-99.54%
5 Years
-91.33%
10 Years
-

TickerPriceChg.Chg.%
APVO0.19940.020411.40
AAPL189.37-1.0300-0.54
GOOG136.40-2.2200-1.60
MSFT378.85-3.8500-1.01
XOM102.34-1.5600-1.50
WFC43.780.41000.95
JNJ152.110.48000.32
FB196.640.99000.51
GE118.860.01000.01
JPM154.320.78000.51
Financial StrengthValueIndustryS&P 500US Markets
2.80
3.20
0.34
0.64
-
Leverage Ratio 3.40
ProfitabilityValueIndustryS&P 500US Markets
82.60
-368.70
-354.00
-329.90
99.40
RevenueValueIndustryS&P 500US Markets
3.11M
0.61
-28.67
-23.90
Earnings HistoryEstimateReportedSurprise %
Q02 2023-1.12-1.23-9.82
Q01 2023-1.190.26121.85
Q03 2022-1.64-1.536.71
Q02 2022-1.33-1.86-39.85
Q01 2022-1.15-1.59-38.26
Q03 2021-1.48-1.452.03
Q02 2021-1.95-1.788.72
Q01 2021-1.62-1.74-7.41
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.3737.29Positive
12/2023 FY-1.7821.24Positive
3/2024 QR-0.3684.81Positive
12/2024 FY-1.33--
Next Report Date-
Estimated EPS Next Report-0.72
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume501.01K
Shares Outstanding17.62K
Shares Float16.97M
Trades Count918
Dollar Volume97.92K
Avg. Volume421.87K
Avg. Weekly Volume245.61K
Avg. Monthly Volume551.93K
Avg. Quarterly Volume468.07K

Aptevo Therapeutics Inc. (NASDAQ: APVO) stock closed at 0.1994 per share at the end of the most recent trading day (a 11.4% change compared to the prior day closing price) with a volume of 501.01K shares and market capitalization of 3.51M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Aptevo Therapeutics Inc. CEO is Marvin L. White.

The one-year performance of Aptevo Therapeutics Inc. stock is -94.19%, while year-to-date (YTD) performance is -91.41%. APVO stock has a five-year performance of -91.33%. Its 52-week range is between 0.1517 and 7.2, which gives APVO stock a 52-week price range ratio of 0.68%

Aptevo Therapeutics Inc. currently has a PE ratio of 1.70, a price-to-book (PB) ratio of 0.70, a price-to-sale (PS) ratio of 3.79, a price to cashflow ratio of -, a PEG ratio of -, a ROA of 14.89%, a ROC of 25.59% and a ROE of 58.32%. The company’s profit margin is 99.40%, its EBITDA margin is -354.00%, and its revenue ttm is $3.11 Million , which makes it $0.61 revenue per share.

Of the last four earnings reports from Aptevo Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.72 for the next earnings report. Aptevo Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aptevo Therapeutics Inc. is Strong Buy (1), with a target price of $18, which is +8 927.08% compared to the current price. The earnings rating for Aptevo Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aptevo Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aptevo Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.38, ATR14 : 0.03, CCI20 : -39.14, Chaikin Money Flow : -0.06, MACD : -0.03, Money Flow Index : 50.97, ROC : -14.42, RSI : 39.38, STOCH (14,3) : 43.92, STOCH RSI : 1.00, UO : 47.30, Williams %R : -56.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aptevo Therapeutics Inc. in the last 12-months were: Daphne L. Taylor (Option Excercise at a value of $0), Grant Grady (Sold 0 shares of value $0 ), Jeffrey G. Lamothe (Option Excercise at a value of $0), Kunz Barbara (Sold 0 shares of value $0 ), Kwon Soyoung (Sold 0 shares of value $0 ), Lamothe Jeffrey (Sold 0 shares of value $0 ), Marvin L. White (Option Excercise at a value of $0), Niederhuber John (Sold 0 shares of value $0 ), So Young Kwon (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a biosciences company. The company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline product includes Otlertuzumab, APVO414, Multiple ADAPTIR Candidates, ALG.APV-527, APVO436 and APVO210.

CEO: Marvin L. White

Telephone: +1 206 838-0500

Address: 2401 4th Avenue, Seattle 98121, WA, US

Number of employees: 80

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

59%41%

Bearish Bullish

56%44%

 

News

Stocktwits